Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcutis Biotherapeutics (ARQT) Non-Current Assets: 2020-2024

Historic Non-Current Assets for Arcutis Biotherapeutics (ARQT) over the last 5 years, with Dec 2024 value amounting to $13.1 million.

  • Arcutis Biotherapeutics' Non-Current Assets rose 59.55% to $21.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $21.8 million, marking a year-over-year increase of 59.55%. This contributed to the annual value of $13.1 million for FY2024, which is 19.53% up from last year.
  • Arcutis Biotherapeutics' Non-Current Assets amounted to $13.1 million in FY2024, which was up 19.53% from $10.9 million recorded in FY2023.
  • Over the past 5 years, Arcutis Biotherapeutics' Non-Current Assets peaked at $13.1 million during FY2024, and registered a low of $5.4 million during FY2021.
  • For the 3-year period, Arcutis Biotherapeutics' Non-Current Assets averaged around $12.0 million, with its median value being $11.9 million (2022).
  • In the last 5 years, Arcutis Biotherapeutics' Non-Current Assets skyrocketed by 120.64% in 2022 and then fell by 7.87% in 2023.
  • Yearly analysis of 5 years shows Arcutis Biotherapeutics' Non-Current Assets stood at $5.4 million in 2020, then dropped by 1.18% to $5.4 million in 2021, then spiked by 120.64% to $11.9 million in 2022, then dropped by 7.87% to $10.9 million in 2023, then grew by 19.53% to $13.1 million in 2024.